Hudson Robotics Inc.’s RapidPick ACIS Automated Colony Isolation System has samples of strains of bacteria, which are plated in sterile colony plates.
Leica Microsystems’s clinical workflow solution combines the Digital Image Hub Enterprise with the SlidePath Gateway.
Biologic Formulation Workflow by Freeslate Inc. automates sample preparation and stressing in addition to formulation analysis.
BAC BV, a provider of antibody based affinity purification technology, announced the addition of a bioprocess affinity chromatography resin to GE Healthcare Life Sciences' portfolio of custom-designed media.
Applied Precision Inc. has launched the DeltaVision OMX Blaze, a research microscopy system designed to reach the next level in the evolution of super-resolution imaging by employing an ultra-fast illumination module and high-speed camera technologies.
Caliper Life Sciences, Inc. announced that its Caliper Discovery Alliances and Services unit has launched a new services offering developed in collaboration with Pfizer Inc.
After nine years as the world’s biggest maker of medicines, Pfizer is set to cede its crown next year to a company that a decade ago few would have predicted to be leading the pharma league tables – Sanofi.
PLX-PAD cells from Pluristem Therapeutics, Inc. met all the clinical studies’ protocol endpoints, demonstrating a safe immunologic profile at all dosage levels and found to be potentially effective in treating patients suffering from critical limb ischemia.
Following ImmuPharma’s Investigational New Drug filing with the FDA and the successful completion of a Phase 2b study, the FDA has granted Lupuzor Fast Track designation.
Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.
Procter & Gamble Co. said that it has combined some of its drug units with Jerusalem-based Teva Pharmaceutical Industries Ltd., a move that should help the companies expand in China and other emerging markets.
Drug maker GlaxoSmithKline PLC said that it has agreed in principle with the United States government on a $3 billion settlement of investigations of the company's sales and marketing practices.
To sustain medical innovation, the U.S. Food and Drug Administration must accelerate the adoption of a benefit-risk framework to inform decision-making in the regulatory process.
Regulus Therapeutics Inc. announced that the Australian Patent Office has granted claims in the ‘Sarnow’ patent series for microRNA-122 therapy in the treatment of hepatitis C viral infections.